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1. Introduction 
Gliomas are the most common malignant cancer affecting the CNS, accounting for 60% of 
primary brain tumors (DeAngelis, 2001; Yiu&He, 2006). The majority of gliomas in adults 
are highly malignant with a poor prognosis, in particular with high-grade tumors such as 
glioblastoma multiforme. Current therapy with surgery, radiation, and chemotherapy 
rarely, if ever, cures the disease and infrequently prolongs life for 1 year (Curran et al., 1993; 
Bao et al., 2006). Additional considerations focus on developing novel modalities to increase 
anti-glioma effects and decrease side-effects. 
Differentiation therapy, using agents that modify cancer cell differentiation, has shown 
promise in the spectrum of agents used against tumors (Leszczyniecka et al., 2001). Wang 
and Chen demonstrated the clinical application for differentiation therapy by introducing 
all-trans-retinoic acid to clinical use for the treatment of acute promyelocytic leukemia 
(APL) (Huang et al., 1988; Wang&Chen, 2000). Notably, the inorganic toxicant arsenic 
trioxide (As2O3), a well known environmental carcinogen, has been also proven to be an 
effective drug in the treatment of APL patients by triggering apoptosis and differentiation of 
APL cells in a dose-dependent manner (Shen et al., 1997; Kinjo et al., 2000). Such excellent 
effects, however, were not reproduced in other hematological and, particularly, solid 
tumors. Differentiation agents for malignant gliomas remain a real challenge. 
In this chapter, we base on our research and mainly discuss proteins or molecules capable of 
inducing differentiation via targeting cAMP/cAMP-dependent protein kinase A (PKA) 
signal pathway and crucial factors such as glycogen synthase kinase-3ǃ (GSK-3ǃ) and 
hypoxia-inducible factor-1ǂ (HIF-1ǂ) determining the efficiency of these drugs. Although 
agents for differentiation therapy have wide application prospect, their real therapeutic 
potentiality remains to be further realized.  
2. The molecular mechanism for differentiation therapy of malignant glioma 
2.1 cAMP/PKA signaling activators induce malignant glioma cell differentiation 
cAMP/PKA signaling has been reported to play important roles in multiple physiological 
processes, including growth, differentiation, gene regulation, and apoptosis (Walsh&Van 
Patten, 1994). Disruption of the PKA catalytic subunit causes destabilization of the diploid 
cell cycle, and the cells start meiosis under conditions repressive for wild-type meiosis 
(Maeda et al., 1994). Ample evidences indicate that cAMP-elevating stimuli such as N-
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substituted cAMP analogues and cAMP-increasing reagents can induce cell differentiation 
in gliomas (Takanaga et al., 2004; Van Kolen&Slegers, 2004). 
2.1.1 Biotoxin-cholera toxin 
Cholera toxin is the major virulent factor of Vibrio cholerae and is the most recognizable 
enterotoxin causing diarrhea, the disease second only to cardiovascular disease as causes of 
death (Goodman&Segreti, 1999). Cholera toxin catalyzes ADP-ribosylation of Gs protein 
and results in accumulation of cellular cAMP (Moss&Vaughan, 1979; Guerrant et al., 1994). 
Guerrant et al. reports that active whole cholera toxin, but not inactive choleragenoid, 
produces elevation of cAMP and parallel morphological changes in CHO cells (Guerrant et 
al., 1974). Ganglioside GM1 reaction with the B subunit of cholera toxin is reported to induce 
neuron-like differentiation of PC12 and neuroblastoma cells (Masco et al., 1991; Kimura et 
al., 2001). All of the findings mentioned above reveal the potential of cholera toxin, a kind of 
biotoxin, in the differentiation induction of tumor cells.  
In Li’s study (Li et al., 2007), rat malignant glioma cell line C6 cells in conjunction with 
primary cultured human glioma cells, which are much more clinically relevant, are used to 
characterize the effect of cholera toxin on the key malignant phenotypes of malignant 
glioma cells to see whether it induces differentiation in them. Cholera toxin triggers cell 
transformation indicative of the cells’ differentiation into a more mature astrocytic state 
(Figure 1a and 1c). This differentiation potential is further confirmed by an increased 
 
 
Fig. 1. Morphological transformation, GFAP and Ki-67 expression induced by cholera toxin 
in rat glioma cell line C6 cells and primary cultured human glioma cells. 
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 expression of GFAP, a 50-kDa type III intermediate filament protein considered to be a 
reliable differentiation marker of normal astrocytes (Roymans et al., 2001), and a lowered 
amount of Ki-67 protein (Figure 1b and 1d). The Ki-67 antigen presents during all active 
phases of the cell cycle but is absent from resting cells exclusively in the nuclei of cycling 
cells; the defined period of nuclear expression makes it a reliable marker of malignant 
proliferating cells (Schluter et al., 1993; Shachaf et al., 2004). In further experiments (Shu et 
al., 2011), the cholera toxin-induced GFAP expression is proved to be mediated by an 
oncogenic pathway interleukin-6/janus kinase 2/signal transducer and activator of 
transcription 3 (IL-6/JAK2/STAT3) cascade, implies that a survival-promoting signal may 
also play a differentiation-supporting role in malignant gliomas (Figure 2). However, the B 
subunit of cholera toxin (choleragenoid) at a dose of 10 ng/ml and even 10 μg/ml does not 
cause any alterations on cell morphology, GFAP expression and proliferation in C6 glioma 
cells (Figure 3). A mechanism that cholera toxin specifically activates ganglioside GM1 and 
induces differentiation in C6 glioma cells is therefore eradicated.  
 
 
Fig. 2. Activation of IL-6/JAK2/STAT3 contributes to GFAP induction during the cholera 
toxin-induced differentiation in C6 glioma cells. 
The regulation of cell proliferation and terminal differentiation is a critical aspect of normal 
development and homeostasis, but is frequently disturbed during tumorigenesis. Cell 
proliferation and differentiation are specifically controlled in the G1 phase and the G1/S 
phase transition in the cell cycle (Nurse, 2000). In differentiation triggered by cholera toxin, 
cellular proliferation inhibition is observed but not significant cell death and accumulation 
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of cells in the G0/G1 phase of the cell cycle at multiple points within the machinery 
governing the G1/S transition is concurrent (Figure 4a-c and Table 1). The expression of G1 
control proteins cyclin D1 and Cdk2 is down-regulated and associated with profound 
increased p21Cip1 and p27Kip1 protein levels (Figure 4d). Cyclin D1 is a critical regulator 
involved in cell-cycle progression through the G1 phase into the S phase, thereby 
contributing to cell proliferation. Cyclin D1 expression is significantly correlated with the 
degree of malignancy, invasion and prognosis of patients in a variety of human carcinomas, 
including glioma (Arato-Ohshima&Sawa, 1999; Lamb et al., 2003). The Cdk inhibitors 
p21Cip1 and p27Kip1 play an important role in mediating growth arrest and are thought to 
function as brakes of the cell cycle (Sherr&Roberts, 1999). The downregulation of cyclin D1 
and overexpression of p21Cip1 and p27Kip1 might therefore be a pivotal candidate for the 
perturbed cell-cycle progression and differentiation induced by cholera toxin. 
 
 
Fig. 3. The B subunit of cholera toxin does not cause any alterations on cell morphology, 
GFAP expression, and proliferation in C6 glioma cells. 
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Fig. 4. Cholera toxin inhibits cell proliferation and alters the protein expressions of cell-cycle 
regulatory molecules in C6 glioma cells. 
 
 
Table 1. Cholera toxin causes a G0/G1-phase cell cycle arrest in C6 and human primary 
glioma cells. 
One of the potential downstream signaling targets of PKA is the CREB protein, an inducible 
transcription factor. Phosphorylation of Ser-133 is a critical event in CREB activation, 
leading to an increase of transcriptional activation by the recruitment of additional 
coactivators. The phosphorylation of CREB by PKA-mediated cAMP-dependent signaling 
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cascade responds to a variety of external signals and appears to play crucial roles in 
differentiation and neurite outgrowth in multiple cell lines (Masson et al., 1993; Impey et al., 
2004; Sato et al., 2006). Cells from transgenic mice expressing a dominant-negative form of 
CREB show a profound proliferative defect and G1 cell-cycle arrest in response to a number 
of different activation signals (Barton et al., 1996). It remains to be explored, however, 
whether PKA/CREB signaling participates in the differentiation of malignant glioma cells. 
In cholera toxin-treated glioma cells, a cholera toxin-induced cAMP increase is able to 
trigger the activation of downstream effectors, as evidenced by PKA activation and CREB 
transcription factor phosphorylation (Figure 5a). In addition, the essential role of PKA 
 
Fig. 5. Cholera toxin-induced differentiation is inhibited by PKI or depletion of CREB. 
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 activation in the cholera toxin-induced differentiation process is supported by experiments 
showing that differentiation is impaired if PKA activity is inhibited by PKI added before the 
differentiating agent cholera toxin or depletion of CREB by siRNA (Figure 5b and 5c). These 
data indicate that differentiation triggered by cholera toxin is effected through the 
PKA/CREB pathway and suggest the requisite role of PKA and transcription factor CREB 
for cholera toxin-induced differentiation. 
In conclusion, cholera toxin might be an astrocytic differentiation-inducing agent in rat C6 
and primary cultured human glioma cells of intensified therapeutic interest in the treatment 
of glioma. This effect may be caused by G1 arrest in the cell cycle ascribed to the restrain of 
cyclin D1 and Cdk2 activities by augmented expression of p21Cip1 and p27Kip1 proteins. Of 
the various possibilities for cholera toxin-induced differentiation, elevated PKA/CREB 
signaling pathway represents a plausible candidate. Significantly, cholera toxin, the 
traditional bacterial toxin, may be a novel agent with substantial differentiation potential in 
the therapy of malignant glioma. Future studies, however, should extend these findings to 
in vivo tumor models. 
2.1.2 Forskolin and other PKA activators 
Forskolin, a diterpene extracted from the roots of the plant Coleus forskohlii, directly activates 
adenylate cyclase (AC) and catalyzes synthesis of cAMP from ATP to activate PKA. 
Accumulating evidences have reported that forskolin induces the differentiation of human 
monoblast U937 cells, neurocytoma cells and neuroblastoma x rat glioma cell line NG108-15 
cells via elevating cAMP (Ammer&Schulz, 1997; Brodsky et al., 1998; Kim et al., 2004) , 
suggesting forskolin to be a potential candidate of differentiation inducing agents for glioma. 
In accordance with previous reports, forskolin represses cell growth via cell cycle arrest in the 
G0/G1 phase and induces cell differentiation characteristic with elongated processes and 
restoration of GFAP expression when administrated to malignant glioma C6 cells (Figure 6a 
and 6b) (Lu et al., 2009; He et al., 2011). In mechanisms, forskolin promotes C6 cell 
differentiation via regulating the transcription and proteolysis of cyclin D1, and maintenance 
of low cyclin D1 expression is required for its effects on differentiation as demonstrated by 
gain and loss of function studies (Figure 6c and 6d). All the information supports the notion 
that forskolin can be developed into a candidate for the future in differentiation therapy of 
glioma, and cyclin D1 is a promising target for pro-differentiation strategy.  
All data mentioned above also indicates that other cAMP/PKA signaling activators should 
have the same potential to induce cell differentiation and proliferation inhibition. Data in 
Figure 7 show that db-cAMP mimics forskolin’s differentiation effects of cholera toxin on 
cell morphology, GFAP expression, cell proliferation, and cell-cycle distributions in  C6 
glioma cells. 
2.2 GSK-3β controls differentiation of malignant glioma cells 
GSK-3 is an evolutionary conserved, ubiquitous serine/threonine kinase that is highly      
enriched in the brain and consists of 2 distinct isoforms, ǂ and ǃ, in mammals (Woodgett, 
1991). One of the most notable qualities of GSK-3 is the vast number of signaling pathways 
that converge on this enzyme and subsequently an even greater number of biological targets 
(Cohen&Frame, 2001; Jope&Johnson, 2004). Numerous studies have indicated that GSK-3 is 
involved in key functions of the brain and is associated with dysfunction in multiple 
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neurological diseases (Grimes&Jope, 2001). More recent studies indicate a role for GSK-3 in 
the control of neoplastic transformation and tumor development, suggesting that GSK-3 is a 
potential therapeutic target in human cancers. However, most attention has focused on the 
ǃ-isoform of GSK-3 and the exact role of GSK-3ǃ in malignancies remains highly 
controversial due to the conflicting results from different tumor models. Although some 
studies found that GSK-3ǃ is a part of a tumor suppressor complex that phosphorylates the 
oncoprotein ǃ-catenin and that GSK-3ǃ inactivation could possibly lead to tumor promotion 
(Hinoi et al., 2000; Rask et al., 2003), other studies have shown that inhibition of GSK-3ǃ 
suppresses cancer cell proliferation and induces apoptosis by abrogating nuclear factor NF-κB 
mediated gene transcription (Ougolkov et al., 2005; Ougolkov et al., 2007). In addition, the vast 
majority of research on GSK-3ǃ has been focused on the aspects of proliferation and apoptosis, 
and little is known about its possible role involved in the process of cancer cell differentiation. 
In differentiation-sensitive C6 and U87-MG malignant glioma cells, intensive GSK-3ǃ is 
highly expressed and activated during the cholera toxin-induced differentiation, whereas 
the GSK-3ǂ activity remains stable. In differentiation-resistant U251 and T98G glioma cells, 
GSK-3ǃ is lowly expressed (Figure 8a). Inhibition of GSK-3ǃ activity or knockdown of its 
expression by small interfering RNA (siRNA) suppresses this differentiation (Figure 8b), 
whereas constitutively active S9A-GSK-3ǃ initiates robust differentiation in differentiation-
resistant U251 glioma cells (Figure 8c). These results indicate that GSK-3ǃ overexpression 
and activation possibly is a contributory event in the process of cellular differentiation in 
malignant gliomas. In addition, ubiquitin/proteasome-dependent degradation is identified 
the major pathway responsible for cyclin D1 reduction and sequential differentiation. By 
further experiments, GSK-3ǃ is confirmed to regulate differentiation by triggering cyclin D1 
translocation and degradation (Figure 9).  
To extend these findings to clinical malignant gliomas, a series of 10 primary cell cultures 
grown from 7 Grade III and 3 Grade IV malignant astrocytoma explants are further 
prepared. Exposure to the differentiation agent cholera toxin also results in differentiated 
characteristics with a stellar shape with filamentous processes and increased GFAP 
expression in all the primary cultures examined (Figure 10a). Furthermore, the 
phosphorylated form of GSK-3ǃ shows the same alteration panel as in the rat C6 cell line 
and GSK-3ǃ inhibitors LiCl and SB216732 could block the increased GFAP and decreased 
PCNA levels induced by differentiation agent cholera toxin (Figure 10b). These results 
confirm the findings in C6 cells and, moreover, suggest a general correlation of GSK-3ǃ 
activity with differentiation in malignant glioma cells. 
To further confirm the possibility that GSK-3ǃ expression is associated with sensitivity to 
differentiation therapy, GSK-3ǃ expression in human glioma tissue samples (WHO Grade III 
and IV) is examined by immunohistochemical staining. Tissues are scored on the basis of the 
percentage of GSK-3ǃ-positive tumor cells. As shown in Figure 10c, overexpression of GSK-
3ǃ is observed frequently in the cytoplasm of tumor cells (representative immunostaining 
image from Grade IV malignant glioma tissues), whereas weak expression only is observed 
in the cytoplasm of cells from normal brain. p-GSK-3ǃY216 that represents the active kinase 
form of GSK-3ǃ is also detected to assess the activation state of the protein. Figure 10c shows 
a higher expression of p-GSK-3ǃY216 in malignant gliomas compared with normal brain 
tissues (representative image from Grade IV malignant glioma tissues). The 
immunohistochemical results of GSK-3ǃ expression and its Y216 phosphorylation in 
patients are summarized in Figure 10d. Together, it is likely that overexpression of active 
GSK-3ǃ is a pathological characteristic of clinical malignant gliomas, which are sensitive to 
the induced-differentiation. 
www.intechopen.com
 The Molecular Mechanism for Differentiation Therapy of Malignant Glioma 
 
75 
 
Fig. 6. Forskolin induces differetiation via downregulation of cyclin D1. 
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Fig. 7. Forskolin and db-cAMP induce cell proliferation inhibition and cell differentation in 
C6 glioma cells. 
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Fig. 8. GSK-3ǃ may be a determinant of cellular differetiation in malignant tumor as a 
pathological characteristic of differentiation-sensitive glioma cells. 
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Fig. 9. GSK-3ǃ regulates differentiation by triggering cyclin D1 translocation and 
degradation. 
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Fig. 10. Expression and phosphorylation of GSK-3ǃ in primary human malignant gliomas. 
In summary, GSK-3ǃ initiates resistant glioma cells susceptible to differentiation and loss of 
GSK-3ǃ activity interrupts cyclin D1 proteolysis necessary for the astrocytic differentiation 
of malignant glioma cells. These data provide strong evidence that GSK-3ǃ acts as a tumor 
suppressor to induce cellular differentiation, and thus suppresses tumor development. As a 
pathological characteristic of differentiation-sensitive glioma cells, GSK-3ǃ may be a novel 
therapeutic target and a determinant of cellular differentiation in malignant tumors. The 
data also show that GSK-3ǂ and GSK-3ǃ have distinct biological roles, as the former is not 
involved in the differentiation-inducing mechanism of cholera toxin in malignant gliomas. 
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2.3 HIF-1α blocks differentiation of malignant gliomas 
Solid tumors frequently develop in regions with hypoxia because of an imbalance in oxygen 
supply and consumption. Recent reports indicate that hypoxic microenvironments 
contribute to cancer progression by activating adaptive transcriptional programs that 
promote cell survival, motility and tumor angiogenesis (Harris, 2002; Pouyssegur et al., 
2006). Histopathological analyses frequently reveal the spatial overlap of hypoxia and 
dedifferentiation within solid tumors, suggesting the role of hypoxia in tumor cell 
differentiation (Jogi et al., 2002; Helczynska et al., 2003). However, it is unclear whether 
hypoxia plays a causal role in this relationship.  
Cells within hypoxic regions adapt to this environment by altering their gene-expression 
program, and thus their phenotype (Leszczyniecka et al., 2001). One of the transcription  
factors primarily responsible for this change is the HIF-1 (Semenza, 2003). HIF-1 is a 
heterodimer that consists of a constitutively expressed ǃ subunit (HIF-1ǃ or ARNT) and a 
catalytic a subunit (HIF-1ǂ) (Harris, 2002; Semenza, 2003). At normoxia, HIF-1ǂ is 
hydroxylated at specific proline residues by oxygen-dependent prolyl hydroxylases, leading to 
an interaction with the von Hippel-Lindau tumor suppressor protein (pVHL) ⁄E3 ligase 
complex and subsequent ubiquitin mediated destruction (Maxwell et al., 1999; Ivan et al., 2001; 
Jaakkola et al., 2001). Under hypoxic conditions, HIF-1ǂ escapes from hydroxylation and 
translocates to the nucleus, where it forms a complex with HIF-1ǃ and the cAMP-responsive 
element binding protein (CREB)-binding protein (CBP) ⁄ p300 co-activator, binds to hypoxia-
response elements and transcriptionally modulates target genes (Semenza, 2002). HIF-1 has 
been shown to play critical roles in tumor angiogenesis, glucose metabolism, invasion ⁄ 
metastasis, and response to radiation and chemotherapy (Moeller et al., 2005; Fulda&Debatin, 
2007; Lin et al., 2008; Rankin&Giaccia, 2008; Yang et al., 2008). However, little is known about 
its possible role in the process of cellular differentiation in solid tumors.  
Gliomas are the most common and malignant primary brain tumors in humans and are 
among the most hypoxic tumors known (DeAngelis, 2001; Rong et al., 2006). Glioblastoma 
multiforme, the highest-grade glioma, is characterized by large necrotic areas within the 
tumor mass, which correlates with enhanced resistance to therapy, increased invasiveness 
and a poor prognosis for the patient (Rong et al., 2006). In addition, malignant glioma cells 
could be induced to undergo differentiation towards their normal counterparts and thus 
serve as a faithful model to study molecular mechanisms underlying differentiation defects 
in solid tumors (Takanaga et al., 2004; Li et al., 2007). 
In the present study, cobalt chloride and deferoxamine (DFO) are used to mimic an 
intratumoral mild hypoxia condition, and the data shows that differentiation induced by 
forskolin in rat C6 and primary cultured human malignant glioma cells is reversibly 
inhibited (Figure 11). Deletion of the endogenous HIF-1ǂ gene restores the differentiation 
capacities, even in the presence of cobalt chloride (Figure 12a). In contrast, stabilization of 
HIF-1 with small interfering RNA (siRNA) against VHL, which leads to proteosomal 
degradation of HIF-1ǂ, shows differentiation blockage similar to that induced by cobalt 
chloride (Figure 12b). Furthermore, inhibition of HIF-1ǂ binding to its transcriptional co-
activator CBP⁄ p300 by chetomin abolishes the differentiation-inhibitory effect of HIF-1 and 
attenuates tumor growth in combination with forskolin (Figure 13). 
Analyses of human glioma tissues have suggested a strong correlation between the expression 
of HIF-1ǂ and malignancy (World Health Organization grade). Expression of HIF-1ǂ protein is 
found in all 95 samples (representative immunostaining images are shown in Figure 14a), and 
no obvious staining is observed in the five normal brain samples (a representative image is 
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Fig. 11. Cobalt chloride (CoCl2)  and DFO inhibit differentiation induced by forskolin in C6 
glioma cells. 
 
 
Fig. 12. HIF-1ǂ is required for the differentiation-inhibitory effect of cobalt chloride (CoCl2) 
in C6 cells. 
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shown in Figure 14a). Statistical evaluation reveals that the amount of HIF-1ǂ is significantly 
increased in parallel with increasing glioma grade (Figure 14a). The percentage of HIF-1ǂ-
positive cells in Grade I is 19.4%, while one in Grade II, III and IV is 32.5%, 46.1% and 70.5% 
respectively. Thus, HIF-1ǂ is demonstrated to be broadly accumulated in glioma cells and its 
overexpression is correlated with glioma malignance grading, in other words, higher levels of 
expression of HIF-1ǂ suggest a greater degree of differentiation defects.  
Then, to test the generality of the inhibitory effects of HIF-1ǂ, primary cultured human 
glioma cells are exposured to the differentiation agent forskolin. The result shows that 
forskolin also results in differentiated characteristics, of a stellar shape with filamentous 
processes and increased GFAP expression in the primary glioma cells (Figure 14b). 
However, co-incubation with cobalt chloride blocks the morphological alterations and 
increased the amount of GFAP induced by forskolin (Figure 14b). Quantitative analysis 
indicates that the percentage of GFAP-expressing cells is significantly up-regulated upon 
treatment with forskolin. Moreover, the up-regulation is reversed by cobalt chloride (Figure 
14b). These results confirm the findings in C6 cells and, moreover, suggest a general 
correlation of HIF-1ǂ activity with differentiation in malignant glioma cells.Taken together, 
HIF-1ǂ negatively regulates the differentiation of malignant gliomas and provides new 
insights into the differentiation therapy by targeting the HIF-1ǂ pathway in solid tumors. 
 
 
Fig. 13. Chetomin abrogates the differentiation-inhibitory effect of cobalt chloride in vitro 
and combination of chetomin and forskolin attenuates tumor growth in vivo. 
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Fig. 14. HIF-1ǂ activity is generally correlated with differentiation in malignant gliomas. 
3. Conclusion 
Deviation from the tissue⁄lineage-specific differentiation program is one of the fundamental 
aspects of tumorigenesis (Scott, 1997). The aberrantly differentiated cells show abnormal 
growth characteristics and distinct invasive and metastatic properties (Sell, 2004). Treating 
malignant tumors through the induction of cell differentiation has been an attractive 
concept, but clinical development of differentiation-inducing agents, especially for solid 
tumors, has been limited to date (Leszczyniecka et al., 2001). Several cell lines established 
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from solid tumors are also reported to be differentiated by respective differentiation-
inducers in vitro (Chintharlapalli et al., 2004; El-Metwally et al., 2005; Li et al., 2007; Choi et 
al., 2009). However, this differentiation has not been verified in in vivo animal models or 
clinically, and there exists little convincing explanation for this finding. 
Based on information mentioned above, cAMP/PKA signaling activators such as cholera 
toxin and foskolin is capable of inducing the differentiation of glioma cells highly expressing 
GSK-3ǃ, and overexpression of active GSK-3ǃ can restore differentiation capacity of 
resistant glioma cells. In addition, HIF-1ǂ is confirmed as a negative regulator of the 
differentiation in malignant gliomas, and targeting the HIF-1ǂ pathway can potentiate the 
inhibitory effect of differentiation inducer in solid tumors. We have reasons to believe that 
all information above not only provide reasonable explanation in molecular mechanisms for 
the previous difficulty of differentiation therapy, but also will promote the development of 
differentiation therapy of glioma even solid tumor in future. 
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